...B. Unfortunately, it did not meet our bar or the primary endpoint, so we've discontinued development in that indication and are looking forward to multiple additional readouts and programs from brepocitinib to come. C. In short, we're looking at 10 indications over the next couple of years, with 4 to 5 potentially registrational programs starting in the next fiscal year. D. We expect to advance clinical development for a range of underappreciated pipeline opportunities, including brepocitinib, namilumab and a program that's underappreciated because we haven't talked about it at all, a program that we in-licensed in the second half of 2023. E. We expect to shortly ahead, file our sNDA for VTAMA atopic dermatitis. F. We hope to continue to accelerate revenue growth in psoriasis, and we are really looking forward to the launch in atopic dermatitis. G. When we did the deal with Roche, we asked all of you to be a little patient with us, as we sorted through our best options for allocating what...
